SCHEMBL9872059

SCHEMBL9872059

COCOc1cc(N)c(F)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.43
GAA P10253 2/20 0.39
MAOA P21397 3/20 0.35
TAAR1 Q96RJ0 1/20 0.34
LMNA P02545 1/20 0.33
PPOX P50336 2/20 0.33
POLB P06746 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
ACLY P53396 1/20 0.32
MEN1 O00255 1/20 0.32
USP2 O75604 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
ALOX12 P18054 1/20 0.32
MAPK1 P28482 1/20 0.32
CYP2C19 P33261 1/20 0.32
KMT2A Q03164 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8879337 0.85 L3MBTL1 (0.48) NPC1GAAMAOAPOLBL3MBTL1
SCHEMBL9873170 0.83 NPC1 (0.37) NPC1GAAMAOALMNAPPOX
SCHEMBL8599602 0.82 PPOX (0.45) NPC1GAAMAOALMNAPPOX
SCHEMBL9769754 0.81 NR1I2 (0.41) NPC1GAAMAOATAAR1LMNA
SCHEMBL9684658 0.81 L3MBTL1 (0.44) NPC1GAAMAOALMNAPOLB
SCHEMBL1224878 0.80 NPC1 (0.67) NPC1GAATAAR1LMNAPPOX
SCHEMBL29283664 0.79 ACLY (0.37) TAAR1LMNAPPOXPOLBL3MBTL1
SCHEMBL8604315 0.79 CSNK2A1 (0.49) NPC1GAAMAOAPPOXPOLB
SCHEMBL8876498 0.78 GAA (0.44) NPC1GAAMAOALMNAL3MBTL1
SCHEMBL8599263 0.78 GLA (0.50) NPC1GAAMAOAPPOXPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240336613-A1 HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. 2024-10-10 US disclosed
CN-118159539-A Heteroaryl compounds for the treatment of huntington's disease PTC医疗公司 2024-06-07 CN disclosed
EP-4377317-A1 HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC Therapeutics, Inc. (US) 2024-06-05 EP disclosed
WO-2023009816-A1 HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. (US) 2023-02-02 WO disclosed
US-5017213-A Herbicides NIHON TOKUSHU NOYAKU SEIZO K. K. (JP) 1991-05-21 US disclosed
EP-0351641-A1 1-Phenylpyrrole NIHON BAYER AGROCHEM K.K. (JP) 1990-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240336613-A1 HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, FH NPC1 57/4885GAA 7/4885MAOA 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.